Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces extension of its fundraising round to a current aggregate total of US $125 million (£92 million GBP). The round was led by Bridford Investments Limited and Novator Partners. Demand for Touchlight’s proprietary synthetic DNA vector, dbDNA™, has grown rapidly in the last year. Source: Touchlight press release 15/9/2021